Skip to main content
Year archive

GLENMARK PHARMACEUTICALS LIMITED — 2022 filings

All 18 regulatory filings released by GLENMARK PHARMACEUTICALS LIMITED (4G8B) in 2022, sourced directly from the official regulator.

18 Filings
2022 Period
2022 filings (18)
Filing Released Lang
General Announcement::Settlement and delisting
Regulatory Filings
2022-05-09 English
General Announcement::Glenmark receives tentative ANDA approval for Calcipotriene & Betamethasone Dipropionate Foam
Regulatory Filings
2022-05-09 English
General Announcement::Glenmark receives the India Pharma Innovation of the Year Award from the Government of India
Regulatory Filings
2022-04-27 English
General Announcement::Glenmark becomes the First Pharmaceutical Company to launch Teneligliptin and Pioglitazone
Regulatory Filings
2022-04-25 English
General Announcement::Intimation regarding Notice of Postal Ballot
Regulatory Filings
2022-04-13 English
General Announcement::Glenmark Specialty S.A. receives approval for conducting Clinical Trial of its Novel Molecule
Regulatory Filings
2022-04-11 English
General Announcement::Early redemption
Regulatory Filings
2022-04-08 English
General Announcement::Bond Repurchase
Regulatory Filings
2022-04-07 English
General Announcement::Outcome of the Board Meeting held on 7th April, 2022
Regulatory Filings
2022-04-07 English
General Announcement::Corporate Action
Regulatory Filings
2022-04-04 English
General Announcement::Glenmark Pharmaceuticals receives ANDA approval for Lacosamide Tablets USP
Regulatory Filings
2022-03-21 English
General Announcement::Glenmark inks agreement with Astrazeneca to commercialize its product Pulmicort Respules in Columbia
Regulatory Filings
2022-02-14 English
Financial Statements and Related Announcement::Third Quarter Results
Regulatory Filings
2022-02-11 English
General Announcement::Glenmark launches Nitric Oxide Nasal Spray (FabiSpray) in India
Regulatory Filings
2022-02-09 English
General Announcement::Board Meeting Intimation
Regulatory Filings
2022-02-07 English
General Announcement::Glenmark Specialty S.A. and Lotus International Pte. Ltd. enter into Exclusive Licensing Agreement
Regulatory Filings
2022-01-20 English
General Announcement::Glenmark Pharmaceuticals receives ANDA tentative approval for Regadenoson Injection
Regulatory Filings
2022-01-17 English
General Announcement::Glenmark Specialty S.A. receives NDA Approval by the US FDA for Ryaltris Nasal Spray
Regulatory Filings
2022-01-14 English